UNSPSC 51112017: Sunitinib malate

This classification denotes a tyrosine kinase inhibitor and angiogenesis activator inhibitor with the molecular formula C22H27FN4O2.C4H6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LVX8N1UT73. European Medicines Agency schedules sunitinib malate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22366. The term sunitinib malate is a United States Adopted Name designation. As of Q4 2014, SUNITINIB MALATE remains US FDA's Preferred Term for this commodity.

Sunitinib malate bears US NLM identifiers UMLS ID C1700685 and NCI Concept Code C26673. Most nations, for tariff and trade purposes, schedule sunitinib malate under HS 29337900 and SITC 51561. SMILES: CCN(CC)CCNC(=O)C1C(C([NH]C1C)/C=C\2/C3CC(CCC3NC2=O)F)C.C([C@@H](C(=O)O)O)C(=O)O.

UNSPSC 51112017 Sunitinib malate is a Commodity code for an oncology therapeutic pharmaceutical. State and local governments acquire this drug—a tyrosine kinase inhibitor used to treat renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine cancers—through cooperative purchasing agreements and direct pharmaceutical supply contracts that route products through authorized wholesalers to state health departments, county health systems, correctional facilities, and other public healthcare providers. The procurement scope covers manufacturer pricing for identified National Drug Codes (NDCs), product compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), supply chain management through authorized distribution channels, and contracting terms that typically run two years with optional extensions. Issuing bodies under this code include state departments of health and administration (often coordinating through multistate cooperative purchasing alliances), county correctional health programs, and state hospital systems that require continuous generic pharmaceutical supply agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP) on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026. The solicitation (S1070000015802) establishes multiple contracts across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with evaluation weighted heavily on price competitiveness (75 percent), fixed pricing (10 percent), and compliance with administrative and EDI requirements (10 percent combined). Contract awards are effective July 1, 2026, with a two-year term and vendor performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines.